SWIFT BIOTECHNOLOGY

Swift is developing state of the art technologies that will save lives and save their health care system billions of dollars in unnecessary treatments made necessary due to late diagnosis. Swift is initially targeting development of screening modalities for endometrial and ovarian cancer. Their company is also pursuing plans for development of screens for other cancers and delivery systems which can transport treatment regimens by novel means in a site-specific manner. Swift Biotechnology is partnering with the University of South Alabama’s Mitchell Cancer Institute, the premier cancer research facility on the Gulf Coast, and their offices are located on the premises.